{
    "nctId": "NCT05957939",
    "briefTitle": "Targeting Metastatic Breast Cancers by Alkaline Glucosodiene Molecules Via a Metabolic Pathway Phase I Clinical Trial",
    "officialTitle": "Targeting Triple-negative Breast Cancer or ER-positive, PR Positive her2 Negative by Alkaline Glucosodiene Molecules Via a Metabolic Pathway Phase I Clinical Trial",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "TNBC - Triple-Negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 2,
    "primaryOutcomeMeasure": "the Progression-free survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Type of patient: Female patient\n* Age: 18-55 years\n* Type of breast cancer: metastatic breast cancer hormonal or triple-negative breast cancer\n\nExclusion Criteria:\n\n* with other co-morbidities like diabetes or hypertension\n* with other type of cancers\n* on other chemotherapy or immunotherapy or hormonal therapy",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}